Drug Search Results
More Filters [+]

Boceprevir

Alternative Names: boceprevir, victrelis, sch 503034
Latest Update: 2024-05-08
Latest Update Note: News Article

Product Description

Boceprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor that was used in combination with peginterferon and ribavirin in the treatment of chronic hepatitis C, genotype 1. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Boceprevir)

Mechanisms of Action: HCV-NS3/4A Inhibitor,SP

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Brazil | Canada | Chile | Colombia | Dominican Republic | European Medicines Agency | Germany | Hungary | Ireland | Italy | Lithuania | Morocco | New Zealand | Peru | Philippines | Portugal | Russia | Slovenia | Spain | Sweden | Taiwan | Thailand | United Kingdom | Vietnam

Approved Indications: Liver Cirrhosis | Hepatitis | Hepatitis, Chronic | Hepatitis C | Hepatitis C, Chronic

Known Adverse Events: Dysgeusia | Headache | Anemia

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Boceprevir

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Recent News Events